Log in to search using one of your social media accounts:

 

Dead is dead: Drug for helping smokers quit found to increase risk of heart attack AND self-harm

(Natural News) Pfizer’s flagship smoking cessation drug varenicline, sold under the brand names Chantix in the United States and Champix in Canada and Europe, may do more harm than good as recent research published in the American Journal of Respiratory and Critical Care Medicine showed that the medication was associated with an increased likelihood of suffering from cardiovascular conditions. A...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news

Related Links:

Young ED Heart Attack When things like this happen...and you are seeing 2-3 patients per hour, sending folks home whom you just barely met
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
Conclusions1,4-Naphthoquinones retained necrosis avidity and [131I]naphthazarin (6) rapidly visualized necrotic myocardium. The necrosis avidity mechanism of [131I]naphthazarin (6) may be attributed to its binding with exposed DNA in necrotic tissues.
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
(Natural News) Many studies have proven time and again that breastfeeding has many long-term and short-term benefits for infants, but did you know that it can also benefit mothers? In a recent study, researchers analyzed data from 289, 573 mothers in China who breastfed their babies. Based on the results, at least 10 percent of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
Condition:   Myocardial Infarction Interventions:   Drug: Cardiac Drug;   Drug: Placebos Sponsors:   John Paul II Hospital, Krakow;   KCRI;   National Center for Research and Development, Poland Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ischemic Heart Disease;   Acute Myocardial Infarction Interventions:   Biological: Stage 1-Low dose VM202;   Biological: Stage 1-Middle dose VM202;   Biological: Stage 1-High dose VM202;   Drug: Stage 2-Placebo;   Biological: Stage 2-Low dose VM202;   Biological: Stage 2-High dose VM202;   Device: C-Cathez® Catheter Sponsor:   ViroMed Co., Ltd. dba VM BioPharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Myocardial Infarction Interventions:   Drug: Cardiac Drug;   Drug: Placebos Sponsors:   John Paul II Hospital, Krakow;   KCRI;   National Center for Research and Development, Poland Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ischemic Heart Disease;   Acute Myocardial Infarction Interventions:   Biological: Stage 1-Low dose VM202;   Biological: Stage 1-Middle dose VM202;   Biological: Stage 1-High dose VM202;   Drug: Stage 2-Placebo;   Biological: Stage 2-Low dose VM202;   Biological: Stage 2-High dose VM202;   Device: C-Cathez® Catheter Sponsor:   ViroMed Co., Ltd. dba VM BioPharma Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Cardiac myocytes, like kidney podocytes, have a limited capacity to regenerate, and myocyte injury and loss contribute to cardiac fibrosis, pathologic remodeling, and heart failure. The paucity of therapeutic options to address heart failure and chronic kidney disease has drawn attention to the role of the Hippo pathway and its downstream effector Yes-associated protein (YAP) in both the heart and kidney. Ongoing clinical trials of a small molecule YAP inhibitor as adjunctive therapy for several common cancers further highlight the importance of understanding the role of this pathway.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Nephrology Digest Source Type: research
(Natural News) International Laboratories voluntarily recalled a single lot of its clopidogrel tablets largely due to drug mislabeling, a Cardiovascular Business report revealed. According to the report, bottles of 30 tablets contained simvastatin instead of clopidogrel. The company sent out letters to its distributors and customers to alert them of the error. International Laboratories also arranged for a return of...
Source: NaturalNews.com - Category: Consumer Health News Source Type: news
More News: Canada Health | Cardiology | Cardiovascular | Chantix | Heart | Heart Attack | Pfizer | Respiratory Medicine | Smokers | USA Health